clinical trial · NCT07871409
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
ObesityOverweightMaridebart cafraglutideAutoinjector
brief summary
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
started
Oct 15, 2026
primary completion
Jun 16, 2027
completion
Sep 8, 2027
last updated
Nov 9, 2026
official title
A Phase 3 Multicenter, Open-label, Single-arm Trial Evaluating Home Self-Administration of Subcutaneous Maridebart Cafraglutide Via Autoinjector in Adult Participants Living With Obesity or Overweight Without Type 2 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol